The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Johnson & Johnson said on Wednesday it temporarily paused the rollout of its Varipulse heart device in the United States as ...

Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external ...

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued success for pulsed field ablation as trends to watch this year.

Quantum computing stocks are having a tumultuous week, but one fund manager says investors should focus on the long game when ...

Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...